A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT06136741 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Atopic Dermatitis

Interventions

DRUG: Rezpegaldesleukin
DRUG: Placebo

Sponsor

Nektar Therapeutics